DGAP-News: PAION AG / Key word(s): Research Update
PAION AG: RECRUITMENT OF PHASE II/III STUDY WITH SHORT-ACTING
ANAESTHETIC/SEDATIVE REMIMAZOLAM (ONO'S DEVELOPMENT CODE: ONO-2745) IN
JAPAN IS COMPLETED
08.05.2013 / 11:06
---------------------------------------------------------------------
RECRUITMENT OF PHASE II/III STUDY WITH SHORT-ACTING ANAESTHETIC/SEDATIVE
REMIMAZOLAM (ONO'S DEVELOPMENT CODE: ONO-2745) IN JAPAN IS COMPLETED
Aachen (Germany), 08 May 2013 - The biopharmaceutical company PAION AG
(ISIN DE000A0B65S3; Frankfurt Stock Exchange, General Standard: PA8) today
announces that its partner, Ono Pharmaceutical Co., Ltd. ('ONO') has
published, that the recruitment of the Phase II/III study with Remimazolam
for general anaesthesia is completed. Remimazolam was administered during
anaesthesia to 375 surgery patients.
The objective of this study was to investigate efficacy and safety of
Remimazolam in induction and maintenance of general anaesthesia in a
multicenter randomized parallel-group study compared to propofol in surgery
patients requiring general anaesthesia.
ONO entered into the license agreement with PAION UK Ltd. (former CeNeS
Limited) in 2007 to develop and commercialize Remimazolam in Japan and is
developing the substance for the Japanese market for both 'induction and
maintenance of anaesthesia' and 'ICU sedation'.
'Again Ono has beaten our expectations and we expect that the excellent
efficacy and safety profile seen in the previous studies will be
confirmed', said PAION CEO Dr Wolfgang Söhngen. 'This will add to the
current momentum in the ongoing discussions to fund the development outside
of Japan.'
###
About PAION
PAION AG is a publicly-listed biotech company headquartered in Aachen,
Germany with a second site in Cambridge, UK. The company has a track record
in developing hospital-based treatments for which there is substantial
unmet medical need. PAION AG is transforming its business model from a pure
development company to a specialty pharmaceutical company with a focus on
anaesthesia products to take advantage of the unique profile of its main
compound, Remimazolam.
About Remimazolam
Remimazolam is an innovative short-acting general anaesthetic/sedative. Due
to its short duration of action and good controllability, it has a
preferable efficacy and safety profile relative to other currently marketed
anaesthesia compounds. The rapid offset of Remimazolam's effect is due to
its metabolism by tissue esterase enzymes that are widely distributed
throughout the body.
Remimazolam has potential in three indications:
- Procedural sedation (e.g. colonoscopies, Phase IIb completed: PAION)
- General anaesthesia (Phase II/III ongoing: ONO; Phase II in
preparation: PAION)
- ICU sedation (Phase II ongoing: ONO)
Remimazolam is available for licensing outside Japan and China, where the
compound is partnered with Ono Pharmaceutical and Yichang Humanwell,
respectively.
Contact
Ralf Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12, 52062 Aachen - Germany
Phone +49 241 4453-152
E-mail r.penner@paion.com
http://www.paion.com
Disclaimer:
This release contains certain forward-looking statements concerning the
future business of PAION AG. These forward-looking statements contained
herein are based on the current expectations, estimates and projections of
PAION AG's management as of the date of this release. They are subject to a
number of assumptions and involve known and unknown risks, uncertainties
and other factors. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ materially from any
future results and developments expressed or implied by such
forward-looking statements. Considering the risks, uncertainties and other
factors involved, recipients should not rely unreasonably upon these
forward-looking statements. PAION AG has no obligation to periodically
update any such forward-looking statements to reflect future events or
developments.
End of Corporate News
---------------------------------------------------------------------
08.05.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: PAION AG
Martinstr. 10-12
52062 Aachen
Germany
Phone: +49 (0)241-4453-0
Fax: +49 (0)241-4453-100
E-mail: info@paion.com
Internet: www.paion.com
ISIN: DE000A0B65S3
WKN: A0B65S
Listed: Regulierter Markt in Frankfurt (General Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
210279 08.05.2013
DGAP-News: PAION AG: RECRUITMENT OF PHASE II/III STUDY WITH SHORT-ACTING ANAESTHETIC/SEDATIVE REMIMAZOLAM (ONO'S DEVELOPMENT CODE: ONO-2745) IN JAPAN IS COMPLETED
| Source: EQS Group AG